Market Live
Sun. Apr 14th, 2024

Aurobindo Pharma | USFDA Approval – Aurobindo Pharma Limited has received final approval from the USFDA to manufacture and market their version of Mometasone Furoate Monohydrate Nasal Spray, which is equivalent to Nasonex Nasal Spray. – This new product will be launched in the first quarter of fiscal year 2025, potentially opening up new revenue streams for the company

By earn Mar 20, 2024 #market
Spread the love

Aurobindo Pharma | USFDA Approval

– Aurobindo Pharma Limited has received final approval from the USFDA to manufacture and market their version of Mometasone Furoate Monohydrate Nasal Spray, which is equivalent to Nasonex Nasal Spray.
– This new product will be launched in the first quarter of fiscal year 2025, potentially opening up new revenue streams for the company

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

By earn

Related Post

WP Twitter Auto Publish Powered By : XYZScripts.com
MUTUAL FUND SIP MONEY TRIPPLE IN 10 YEARS FII DATA 18 SEPTEMBER MIDCAP AND SMALL CAP SHARES SELL MARKET LIVE
Dds benoni hip hop dance school enroll now 083 6102168.